Background {#Sec1}
==========

Mantle cell lymphoma (MCL) is considered as an incurable subtype of non-Hodgkin's lymphoma that causes significant morbidity and early death presumably due to relapsed disease \[[@CR1]--[@CR3]\]. Despite apparent clinical remissions achieved with chemotherapy regimens (R-CHOP or R-hyperCVAD), MCL relapse rates hover around 50 % \[[@CR4], [@CR5]\]. The relapse is considered to be due to chemoresistant cells that prevent complete elimination of MCL cells.

A small fraction of cells within tumors have tumor-initiating properties and are believed to be the source of relapsed cancer. These cells are referred to as cancer stem cells (CSCs) or tumor-initiating cells \[[@CR6]--[@CR9]\]. CSCs have been implicated in the growth, progression, and relapse of several tumor subtypes. The most current therapies target dividing tumor cells while sparing non-dividing and inherently chemoresistant CSCs; thus, they fail to provide long-term cures and result in tumor relapse \[[@CR10], [@CR11]\].

CSCs and normal hematopoietic stem cells share Wnt, Notch, and Hedgehog signaling pathways, which are required for their growth and self-renewal \[[@CR7]\]. Recent studies have suggested a role of Wnt signaling in MCL tumorigenesis \[[@CR12]--[@CR14]\]. The Wnt signaling pathway regulates development, and its dysregulation leads to oncogenesis \[[@CR15]--[@CR17]\]. Canonical Wnt signaling is initiated by the binding of Wnt ligands to their cognate Frizzled (FZD) receptors and its co-receptors, low density lipoprotein receptor related proteins 5/6 (LRP5/6). In the absence of Wnt signaling, β-catenin is phosphorylated and its interaction with GSK-3β and axin-1 leads to its ubiquitination and degradation \[[@CR18]\]. Activation of the Wnt pathway prevents β-catenin phosphorylation-induced degradation, and stabilized β-catenin accumulates in the nucleus, where it forms active transcription complexes with the T cell factor/lymphoid enhancer binding factor (TCF/LEF) family of DNA-binding transcription factors \[[@CR19]--[@CR21]\]. Dysregulation of Wnt pathway can promote tumorigenesis \[[@CR22], [@CR23]\]. Selective targeting of stem cell signaling pathways should eliminate CSCs \[[@CR24]\].

MCL-initiating cells (MCL-ICs) have been recently identified based on a lack of CD19 marker (CD34-CD3-CD45+CD19- cells) \[[@CR25]\]. Two studies from different groups have shown that these MCL-ICs can repopulate tumor in mice \[[@CR25], [@CR26]\]. As few as 100 of CD19- MCL-ICs have been found to produce whole tumor with both CD19+ and CD19- cells, while CD19+ MCL-non-ICs were incapable of tumor development at comparable limited dilutions in severe combined immunodeficiency (SCID) mice \[[@CR25], [@CR26]\]. We suggest that the high relapse rates of human MCL arise from incomplete elimination of chemoresistant MCL-ICs \[[@CR27]\]. Thus, in order to improve long-term survival of individuals with MCL, it is important to have a fuller understanding of the signaling pathways responsible for the chemoresistance and maintenance of MCL-ICs. In this study, we investigated the expression and importance of Wnt pathway in survival of MCL-ICs and explored ways to eliminate these cells.

Results {#Sec2}
=======

MCL-ICs possess stem cell-like properties {#Sec3}
-----------------------------------------

Subpopulations of MCL-ICs (CD34-CD3-CD45+CD19-) and MCL-non-ICs (CD34-CD3-CD45+CD19+) were isolated from a MCL tumor sample based on a previously described immunostaining and sorting protocol (Fig. [1a](#Fig1){ref-type="fig"}) \[[@CR25]\]. The purity and identity of the isolated MCL-ICs population was confirmed by a lack of expression of surface markers for plasma cells (CD27, CD38) and natural killer cells (CD56, CD16) (Fig. [1b](#Fig1){ref-type="fig"}). Fluorescence in situ hybridization analysis of isolated MCL-ICs and cyclin D1 expression confirmed the presence of t (11;14) (q13; q32) (Fig. [1c](#Fig1){ref-type="fig"}). Presence of cyclin D1 overexpression in MCL-ICs confirmed that MCL-ICs are clonal cells (Fig. [1d](#Fig1){ref-type="fig"}).Fig. 1Isolation of MCL-ICs. (**a**) Isolation of MCL-ICs using immunostaining and flow sorting. (**b**) Immunostaining of isolated MCL-ICs for plasma cell markers CD27/CD38 and natural killer cell markers CD56/CD16 detected by flow cytometry. (**c**) Detection of gene fusion t (11;14) (q13; q32) in MCL-ICs using fluorescent in situ hybridization, indicated by *arrow*. (**d**) qRT-PCR expression of cyclin D1 in MCL-ICs, MCL-non-ICs relative to B-cells. Differences between MCL-ICs and B-cells were significant (*P* \< 0.05) for cyclin D1

qRT-PCR analysis revealed enrichment of the stem cell core transcription factors Nanog, Oct4, and KLF4 (5.29, 3.06, and \>100-fold, respectively) in MCL-ICs compared with MCL-non-ICs (Fig. [2a](#Fig2){ref-type="fig"}). However, Sox2 expression was not significantly elevated in MCL-ICs (1.07-fold) compared with B-cells (peripheral blood CD19+ cells). qRT-PCR analysis also showed significantly higher (\>100-fold) expression of aldehyde dehydrogenase 1 (ALDH1) and ALDH2 in MCL-ICs than in MCL-non-ICs (Fig. [2b](#Fig2){ref-type="fig"}); this observation concurs with the high ALDH activity detected in MCL-ICs (Fig. [2e](#Fig2){ref-type="fig"}). The expression levels of the antioxidant enzymes MT1b and SOD2 were elevated over sixfold in MCL-ICs, suggesting a higher reactive oxygen species scavenging capacity (Fig. [2b](#Fig2){ref-type="fig"}). MCL-ICs also overexpressed genes associated with chemoresistance, such as those encoding the ATP transporters ABCC3 and ABCC6 as well as CD44 (\>100-, 22-, and 3-fold, respectively) compared with MCL-non-ICs (Fig. [2c](#Fig2){ref-type="fig"}). Cell cycle analysis showed that 100 % of MCL-ICs were quiescent (in G0/G1 phase), whereas MCL-non-ICs were distributed throughout all phases of the cell cycle (G0/G1, 69.2 %; S, 9.16 %; G2/M, 15.5 %) (Fig. [2d](#Fig2){ref-type="fig"}). Taken together, these results indicate that MCL-ICs possess characteristic gene expression of cancer stem cells.Fig. 2Stem cell-like properties of MCL-ICs. **a**--**c** qRT-PCR performed using the total cellular RNA isolated from MCL-ICs (*n* = 4) for **a** stem cell transcription factors (Nanog, Oct4, Sox2, Klf4), **b** ALDH isoforms and antioxidant enzymes SOD2 and MT1b, and **c** chemoresistance-associated genes encoding ABCC3, ABCC6, and CD44. Differences between MCL-ICs and MCL-non-ICs were significant (*P* \< 0.05) for ALDH1, ALDH2, SOD2, MT1b, Nanog, Oct4, Klf4, ABCC3, ABCC6, and CD44. **d** Cell cycle analysis of isolated MCL-ICs, MCL-non-ICs, and total MCL cells by flow cytometry. **e** ALDH activity in freshly isolated MCL-ICs from apheresis samples evaluated using ALDEFLUOR kit

Wnt pathway genes are overexpressed in MCL-ICs {#Sec4}
----------------------------------------------

Analysis from previous studies using unfractionated MCL cells have implicated the Wnt pathway in the pathogenesis of mantle cell lymphoma \[[@CR12]--[@CR14]\]. Therefore, we first investigated Wnt3 expression in unfractionated MCL. Our observations suggest that 9 out of 20, nearly 45 % MCL samples, overexpress Wnt3. We next investigated the expression of Wnt3 in MCL-ICs isolated from MCL samples expressing high and low Wnt3 levels. Our results showed that MCL-ICs were enriched in Wnt3 compared to MCL-non-ICs and B-cells, irrespective of total tumor Wnt3 expression (Fig. [3a](#Fig3){ref-type="fig"}). We observed differential up-regulation of Wnt ligands and their FZD receptors in MCL-ICs compared with MCL-non-ICs (Fig. [3b](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}), using B-cells as a reference. To show other evidence of enhanced Wnt signaling, we performed immunostaining for β-catenin. Higher cellular and nuclear levels of β-catenin were observed in MCL-ICs than in MCL-non-ICs (Fig. [3c](#Fig3){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1) whereas B-cells did not show detectable β-catenin levels (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Activation of Wnt signaling in MCL-ICs was confirmed by the elevated expression of the Wnt target genes encoding ID2 and TCF4 (both \>100-fold) compared with MCL-non-ICs (Fig. [3d](#Fig3){ref-type="fig"}). Thus, by 3 independent methods, we show that the Wnt pathway is differentially up-regulated in MCL-ICs.Fig. 3Enrichment of Wnt signaling pathway genes in MCL-ICs. **a** Expression of Wnt3 in unfractionated MCLs (*n* = 20) and MCL-ICs isolated from unfractionated MCLs expressing high (*n* = 3) and low (*n* = 3) Wnt3. **b** Expression of mRNAs encoding Wnt ligands and FZD receptors in freshly isolated MCL-ICs and MCL-non-ICs relative to B-cells from healthy donors. Horizontal lines represent median for each group. Differences between MCL-ICs and MCL-non-ICs were significant (*P* \< 0.05) for Wnt3, Wnt7b, FZD1, FZD5, FZD9, and FZD6. **c** Immunostaining detection of the expression and localization of β-catenin in freshly isolated MCL-ICs and MCL-non-ICs. Color image is included in Additional file [1](#MOESM1){ref-type="media"}: Figure S1. **d** Relative expression levels of Wnt target genes encoding ID2 and β-catenin--interacting transcriptional factor TCF4 in MCL-ICs (*n* = 4) and MCL-non-ICs (*n* = 4). Differences between MCL-ICs and MCL-non-ICs were significant (*P* \< 0.05) for both genesTable 1qRT-PCR analysis of Wnt ligands and FZD receptor expression in primary MCL cells compared to B-cells from healthy donorsMCL-non-ICsMCL-ICs*P* valueMedian95 % CIMedian95 % CIWnt Ligands Up-regulated in MCL-non-ICs and MCL-ICs  Wnt3a17.5550.12--56.0534.522.49--91.860.0877  Wnt113.660.19--8.9132.610.84--69.970.1588 Up-regulated in MCL-ICs  Wnt5a1.780.76--21.9310.53.56--17.870.3465  Wnt31.490.98--35.3623.324.26--47.610.0500  Wnt8b1.250.39--2.603.891.45--15.160.2308  Wnt41.760.21--6.133.410.54--5.650.2820  Wnt7a1.210.75--5.322.090.60--6.760.2715  Wnt61.020.05--17.651.850.08--8.710.5133  Wnt5b0.660.42--18.8245.470.95--146.300.1956  Wnt10.450.15--12.259.264.18--15.200.1528  Wnt7b0.280.25--2.244.152.13--7.850.0156  Wnt9b0.390.15--1.472.441.08--8.790.1764  Wnt2b0.280.16--8.181.390.05--9.600.0802  Wnt10a0.670.24--14.800.960.03--4.410.5622 Up-regulated in MCL-non-ICs  Wnt9a229.934.51--962.2818.3110.81--304.060.3201  Wnt1611.991.32--32.974.613.23--9.860.3029  Wnt8a6.970.24--18.731.010.15--2.320.1785FZD Receptors Up-regulated in MCL-non-ICs and MCL-ICs  Fz237.314.24--58.2646.9610.01--157.600.2909  Fz74.530.49--9.764.481.89--9.040.9536 Up-regulated in MCL-ICs  Fz41.150.07--2.52122.71.93--13400.3002  Fz11.81.10--7.7625.414.65--37.390.0390  Fz51.430.99--4.457.373.58--8.770.0100  Fz91.440.59--2.754.742.81--8.080.0379  Fz100.640.29--1.444.263.91--10.990.0738  Fz80.130.01--0.390.770.10--4.760.2907 Up-regulated in MCL-non-ICs  Fz65.024.47--5.591.340.66--1.850.0001  Fz30.30.12--7.040.260.24--1.220.4814B-cells (median = 1) are used as reference. Median with 95 % confidence interval limits depicts the variations observed among patient samples. Differences between MCL-ICs and MCL-non-ICs were considered as significant with *P* \< 0.05.*MCL* mantle cell lymphoma, *ICs* initiating cells

Inhibition of Wnt signaling preferentially eliminates MCL-ICs {#Sec5}
-------------------------------------------------------------

Treatment of primary MCL cells with chemotherapeutic drugs (vincristine, doxorubicin, or ibrutinib) induced apoptosis in MCL cells but did not decrease the percentage of MCL-ICs (1.79, 1.57, and 2.18 %, respectively) compared with buffer control (1 % MCL-ICs) suggesting chemoresistance of MCL-ICs to these agents (Fig. [4a](#Fig4){ref-type="fig"}). We analyzed the effects of Wnt signaling inhibitors targeting the pathway either upstream of β-catenin degradation (tankyrase inhibitor XAV939, axin-1 stabilizer IWR1-endo, and porcupine inhibitor IWP2) or downstream at β-catenin-mediated transcription complex (CCT036477, iCRT14, and PKF118-310) (Fig. [5](#Fig5){ref-type="fig"}). MCL cells were treated with the known active concentrations of these inhibitors and evaluated for the percentage of MCL-ICs. None of the agents acting upstream of β-catenin degradation decreased the percentage of MCL-ICs. On the other hand, chemical inhibitors of β-catenin-TCF4 interaction, CCT036477, iCRT14, and PKF118-310, effectively decreased the percentage of MCL-ICs from 1 % in buffer control to 0.35, 0.68, and 0.44 %, respectively (Fig. [4a](#Fig4){ref-type="fig"}) and induced apoptosis of MCL cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). We next examined the effect of the most potent Wnt inhibitor, CCT036477, on the expression of Wnt target genes and transcription factors associated with stemness of MCL-ICs. Treatment with CCT036477 reduced the expression of the Wnt target genes encoding PPARδ, Cyclin D1, TCF4, and ID2 (1.64-, 1.96-, 2.56-, 8.33-, and 12.5-fold, respectively) (Fig. [4b](#Fig4){ref-type="fig"}), and the stem cell-specific core transcription factors Nanog, Oct4, Sox2, Myc, and Klf4 (1.28-, 1.26-, 2-, 3.26-, and 3.67-fold, respectively) (Fig. [4c](#Fig4){ref-type="fig"}). Gli2 was used as off-target negative control. In contrast, inhibitors of Hedgehog and Notch signaling pathways did not decrease the percentage of MCL-ICs (Additional file [3](#MOESM3){ref-type="media"}: Figure S3). Taken together, these results suggest that targeting β-catenin-TCF4 interaction can preferentially eliminate MCL-ICs by effectively blocking Wnt signaling in MCL-ICs.Fig. 4Preferential elimination of MCL-ICs by inhibition of Wnt signaling. **a** Percentage of MCL-ICs evaluated by immunostaining and flow cytometry (as shown in Fig. [1a](#Fig1){ref-type="fig"}) of primary MCL cells (*n* = 3) treated with vincristine (5 nM), doxorubicin (35 nM), or ibrutinib (10 μM), the Wnt inhibitors, CCT036477 (10 μM), iCRT14 (10 μM), or PKF118-310 (10 μM), for 48 h. \*Differences between treated and control group were significant *P* \< 0.05 (**b--c**) qRT-PCR analysis of the expression of (**b**) Wnt target genes encoding PPARδ, Cyclin D1, Myc, TCF4, ID2, and (**c**) stem cell core transcription factors Nanog, Oct4, Myc, Sox2, and Klf4 in MCL-ICs (*n* = 3) treated with 10 μM CCT036477 for 6 h. Gli2 is an off-target control. \**P* \< 0.05Fig. 5Schematic representation of Wnt pathway inhibition by small molecule inhibitors. Wnt pathway is turned off in the absence of Wnt ligand (left); destruction complex involving APC, Axin-1, and GSK-3β interacts with and phosphorylates β-catenin leading to its degradation. Binding of Wnt ligands to their cognate Frizzled (FZD) receptors and its co-receptors, low density lipoprotein receptor related proteins 5/6 (LRP5/6), activates the Wnt pathway (right) leading to sequestration and degradation of Axin-1 and phosphorylation and degradation of GSK-3β. Degradation of destruction complex components leads to accumulation of β-catenin and its subsequent translocation into the nucleus where it interacts with TCF4 to promote transcription of Wnt target genes. IWR1 stabilizes Axin-1 and promotes formation of destruction complex and degradation of β-catenin (*red arrows*). IWP2 inhibits Porcupine-mediated acylation and subsequent secretion of Wnt ligands. XAV939 inhibits Tankyrase-mediated degradation of Axin-1 and thus promotes formation of destruction complex (*red dashed arrow*). CCT036477, iCRT14, and PKF118-310 target β-catenin-TCF4 transcription complex

Discussion {#Sec6}
==========

The high rate of MCL relapse after initial apparent clinical remissions achieved with conventional chemotherapy suggests incomplete elimination of MCL cells and implicates a role for chemoresistant MCL-ICs in relapse. Here we showed that MCL-ICs have functional properties of cancer stem cells: high expression of ALDH, antioxidant enzymes, chemoresistance-associated genes, and stem cell-associated transcription factors, while still retaining t (11;14) (q13; q32) and overexpression of cyclin D1. Our analysis showed that MCL-ICs overexpress a subset of Wnt ligands and FZD receptors and that Wnt signaling is activated in MCL-ICs. Treatment of primary MCL cells with Wnt inhibitors preferentially eliminated MCL-ICs, which was not achieved with the current chemotherapy agents vincristine, doxorubicin, or even with the recently FDA-approved agent ibrutinib \[[@CR28]\]. Burton tyrosine kinase (BTK) has been shown to be a negative regulator of Wnt signaling \[[@CR29]\]. Therefore, it is not surprising that ibrutinib (a BTK inhibitor) probably resulted in inducing Wnt signaling rather than inhibiting it and thereby could not eliminate MCL-ICs. Our results suggest that the inability of conventional chemotherapy to kill MCL-ICs can be overcome by adding inhibitors of Wnt signaling.

A recent study showed that cobble stone area-forming cells (CAFCs) that developed from MCL co-cultured with human mesenchymal stem cells (hMSCs) are the morphologic equivalent of MCL-ICs with the CD34-CD3-CD45+CD19-CD133+ marker phenotype and manifested their tumor-initiating capacity in NOD/SCID mice \[[@CR26]\]. CAFCs were also resistant to bortezomib, fludarabine, and doxorubicin and expressed stem cell transcription factors Nanog and Oct4 but not Sox2 \[[@CR26]\]. The CD34-CD3-CD45+CD19- MCL-ICs characterized in our study are identical to the CAFCs; they were also CD133+ and exhibited the same characteristics. However, our study has further extended the characterization of MCL-IC, by identifying a hyperactive Wnt signaling pathway, crucial for their maintenance and survival.

Our results showed up-regulated expression of canonical ligand Wnt3 \[[@CR30]\] but not of the non-canonical ligands such as Wnt4, Wnt5, and Wnt11 \[[@CR31]\] in MCL-ICs compared to MCL-non-ICs. Immunostaining results also confirmed the differentially higher staining of active unphosphorylated β-catenin in MCL-ICs, which is required for canonical but not for non-canonical Wnt pathway \[[@CR32]\]. In addition, the FZD6 receptor, which is associated with inhibition of canonical Wnt signaling pathway \[[@CR33]\], was not differentially expressed in MCL-ICs. These results clearly indicate the presence of activated canonical Wnt signaling pathway in MCL-ICs.

Other investigators have revealed that Wnt is an important pathway in primary MCL tissues and have implicated this pathway in the pathogenesis of MCL \[[@CR13]\]. Analysis of unfractionated MCL shows only a threefold up-regulation compared to B-cells in the previous study \[[@CR13]\]. Our study showed a 23-fold enhanced Wnt3 expression in MCL-ICs compared to B-cells. These results clearly show the importance of Wnt signaling in MCL-ICs.

MCL is believed to be driven by enhanced cyclin D1 expression due to t (11;14) (q13; q32) present in \>90 % of MCL \[[@CR34], [@CR35]\]. A minority of MCLs do not express cyclin D1 \[[@CR36]\]. However, other isoforms of cyclin D are overexpressed in cyclin D1-negative MCLs, which suggests an indispensable requirement for the expression of at least one isoform of cyclin D in MCL \[[@CR37]\]. Thus, it appears that mechanisms other than t (11;14) (q13; q32) are responsible for the overexpression of at least one other cyclin D in cyclin D1-negative MCL. It is of interest that Wnt signaling could potentially fulfill this role \[[@CR38]--[@CR40]\] as it was shown to up-regulate cyclin D2 expression \[[@CR41], [@CR42]\]. Wnt3 was also noted to be overexpressed in cyclin D1-negative MCL that also lacked t (11;14) (q13; q32) \[[@CR36]\]. Therefore, enhanced Wnt signaling may be the underlying driver of overexpression of cyclin D in all MCL regardless of t (11;14) status.

Overexpression of Wnt ligands and their cognate FZD receptors in MCL-ICs points to the existence of an autocrine signaling loop. Immunostaining of β-catenin and the elevated expression of Wnt target genes encoding ID2 and TCF4 clearly confirmed higher Wnt activity in MCL-ICs than in MCL-non-ICs. However, inhibitors of Wnt signaling acting upstream of β-catenin degradation step had no effect on MCL-ICs. On the other hand, downstream Wnt inhibitors targeting the β-catenin-TCF4 transcription complex (CCT036477, iCRT14, and PKF118-310) preferentially eliminated MCL-ICs over MCL-non-ICs. These findings can be explained either by the very low expression of proteins involved in β-catenin degradation such as GSK-3β and axin-1 (target of XAV939, IWR1-endo, IWP2 compounds) observed in MCL-ICs or by a contribution of redundant and additional pathways to β-catenin activation, such as autocrine fibroblast growth factor receptor signaling \[[@CR43], [@CR44]\]. Further experiments will be required to delineate the major contributors to β-catenin activation in MCL-ICs.

We found elevated levels of FZD1 and its ligand Wnt3 in MCL-ICs as compared to MCL-non-ICs. Other researchers have demonstrated that targeting FZD1 reverses multidrug resistance in neuroblastomas and breast cancer cells \[[@CR45], [@CR46]\]. Thus, Wnt3-FZD1 signaling may be one of the reasons for chemoresistance in MCL \[[@CR47], [@CR48]\].

In summary, we have outlined an enhanced Wnt/β-catenin signaling in MCL-ICs and shown that inhibition of the Wnt pathway effectively eliminates MCL-ICs, which are implicated in MCL relapse. We have also demonstrated that present therapy approaches for MCL, including recently approved drug ibrutinib, do not address the killing of MCL-ICs. Thus, we anticipate that current rates of MCL relapse will not decrease substantially with current therapies. A detailed examination of selectively enhanced signaling in MCL-ICs may be a good starting point to expose pathways important for MCL tumor stem cell survival. Presenting clinical and MCL features at time of initial MCL lymphoma presentation do not identify a priori, who are the patients who will relapse from those will attain cures. Perhaps, studying the MCL-IC and their response to targeting agents will be a key to identify patients who will relapse. Our results clearly show that Wnt signaling inhibitors targeting β-catenin-TCF4 interaction can eliminate MCL-ICs. However, blocking the Wnt pathway exclusively in tumor cells will be challenging, as Wnt signaling also has a role in the self-renewal of non-malignant tissues such as intestinal crypts, and bone growth plates \[[@CR49], [@CR50]\]. Nevertheless, our results point to the important and actionable targets of Wnt signaling in MCL pathogenesis and its potential usefulness as a target for therapy to eliminate MCL-ICs and reduce the risk of MCL relapse.

Conclusions {#Sec7}
===========

Our results clearly demonstrate the differential activation of Wnt pathway in MCL-ICs. Not all steps in the Wnt signaling pathway are amenable to effective blocking in MCL. We show that blocking of Wnt signaling at the β-catenin-TCF4 transcription complex effectively blocks signaling in MCL-IC and preferentially kills the MCL-IC cells, which harbor chemoresistance. This study results shows identification of effective agents in MCL-IC that would not had been possible by studying whole MCL cells. Since inhibition of Wnt pathway resulted in preferential elimination of MCL-ICs, we conclude that Wnt pathway should be targeted to eliminate MCL-ICs and reduce the risk of relapsed MCL.

Methods {#Sec8}
=======

Patients and agents {#Sec9}
-------------------

Cells and clinical information from MCL patients described in this manuscript (Additional file [4](#MOESM4){ref-type="media"}: Table S2) were collected and published with the written informed consent of each patient under The University of Texas MD Anderson Cancer Center IRB-approved clinical protocol LAB08-0190 for use of human tissues.

The following agents were tested: Wnt inhibitors XAV939 (Selleck Chemicals, Houston, TX), iCRT14 (R&D Systems, Minneapolis, MN), CCT036477, PKF118-310 (Sigma-Aldrich, St. Louis, MO), IWP2, IWR1-endo, and IWR1-exo (Santa Cruz Biotechnologies, Santa Cruz, CA); Hedgehog inhibitors GANT61 (R&D Systems, Minneapolis, MN), LDE225 and Cyclopamine (both from Selleck Chemicals, Houston, TX); Notch inhibitor RO4929097 (Selleck Chemicals, Houston, TX).

Isolation of normal B-cells {#Sec10}
---------------------------

Peripheral blood B-cells were isolated from healthy donors' blood obtained from the Gulf Coast Blood Center (Houston, TX) by using CD19-positive magnetic beads and were released with the competitive CD19 DETACHaBEAD according to the manufacturer's instructions (Invitrogen-Life Technologies, San Diego, CA). All procedures were performed under The University of Texas MD Anderson Cancer Center IRB-approved clinical protocol LAB08-0190.

Isolation of MCL cells and MCL-ICs {#Sec11}
----------------------------------

MCL tumor cell-enriched buffy coats were isolated from apheresis or leukemic phase blood of MCL patients by Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) gradient centrifugation. Obtained cells were then stained with antibodies against CD34-APC (Cat No. 555824), CD3-APC-Cy7 (Cat No. 557832), CD45-FITC (Cat No. 555482), CD19-PE (Cat No. 555413), and Sytox blue for selection of live cells (all from BD Bioscience, San Jose, CA). Subpopulations of MCL-ICs (CD34-CD3-CD45+CD19-) and MCL-non-ICs (CD34-CD3-CD45+CD19+) were isolated using a fluorescence-activated cell sorter (Influx, BD Bioscience, San Jose, CA) according to a previously described protocol \[[@CR25]\]. Subpopulations of sorted cells were analyzed for purity by immunostaining with markers for plasma cells (CD27, CD38) and natural killer cells (CD56, CD16) using the antibodies CD27-PerCP-Cy5.5 (Cat No. 560612), CD38-PE-Cy7 (Cat No. 560677), CD56-PE-Cy7 (Cat No. 557747), and CD16-Pacific blue (Cat No. 558122) (all from BD Bioscience, San Jose, CA), respectively.

ALDH activity assay {#Sec12}
-------------------

ALDH activity in cells was determined by using an ALDEFLUOR kit according to the manufacturer's protocol (STEMCELL Technologies, Vancouver, Canada). Briefly, 1 × 10^6^ cells were resuspended in a 1 ml assay buffer with 5 μl of ALDEFLOUR reagent. DEAB was used as inhibitor of ALDH activity. A 500-μl aliquot of the reagent mixed cells was transferred to an Eppendorf tube containing 5 μl of DEAB as a control. Samples were incubated at 37 °C for 45 min. Green fluorescence intensity was measured with a BD Fortessa flow cytometer (Becton Dickinson, San Jose, CA) and evaluated with FlowJo software (Tree Star, Ashland, OR).

Fluorescent in situ hybridization {#Sec13}
---------------------------------

Isolated MCL-ICs, MCL-non-ICs, and B-cells from healthy donors were affixed on slides (Statlab, McKinney, TX) using cytospin. Slides were fixed using SAFETEX cytology spray (Andwin Scientific, Woodland Hills, CA) and hybridized using Vysis IgH/CCND1 probe kit (Abbot molecular, Abbott park, IL) to confirm the presence of t (11;14) (q13; q32). Staining was assessed using a Bioview Duet imaging system (Bioview, Nes Ziona, Israel) equipped with an Olympus BX61 microscope (Olympus America, Center Valley, PA).

Quantitative real-time polymerase chain reaction (qRT-PCR) {#Sec14}
----------------------------------------------------------

Total RNA was extracted from cells using RNAqueous kit according to the manufacturer's protocol (Ambion-Life Technologies, Austin, TX). First-strand cDNA was synthesized using a Superscript III reverse transcriptase kit according to the manufacturer's protocol (Invitrogen-Life Technologies, San Diego, CA). Samples were analyzed on 96-well microtiter plates using the StepOnePlus real-time PCR System (Applied Biosystems, Grand Island, NY). qRT-PCR was performed using SYBR green dye and primers specific for selected human genes (Additional file [5](#MOESM5){ref-type="media"}: Table S1) as described earlier \[[@CR51], [@CR52]\]. PCR was performed with 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Step-One software version 2.1 was used to analyze the qRT-PCR data.

Immunostaining {#Sec15}
--------------

Cells were immobilized on glass slides by using cytospin prior to fixation in methanol for 1 h at −20 °C. Cells were permeabilized using 0.5 % Triton-×100 in PBS for 20 min at room temperature prior to staining with non-phosphorylated (active) anti-β-catenin antibody (1 μg, Cat No. 8814S, Cell Signaling, Danvers, MA) and AlexaFluor-488-conjugated secondary antibody (1:500, Cat No. A11008, Life Technologies, San Diego, CA). Slides were washed with 0.1 % Tween 20 and mounted with ProLong Gold antifade reagent containing nuclear stain 4′,6 diamidino-2-phenylindole dihydrochloride (DAPI) (Invitrogen-Life Technologies, San Diego, CA). Images were acquired at 60× using A1R confocal laser microscope system (Nikon Instruments, Melville, NY).

Growth and treatment of MCL cells {#Sec16}
---------------------------------

Primary MCL cells were seeded onto a layer of human bone marrow mesenchymal stromal cells (hMSCs) at a MCL to a stromal cell ratio of 10:1 and grown in hMSC medium supplemented with mesenchymal cell growth factors and glutamine (Lonza, Allendale, NJ) at 37 °C in 5 % CO~2~ as described previously \[[@CR53]\]. MCL cells were harvested, resuspended in 50 % fresh and 50 % conditioned medium from hMSC cultures, and incubated with the indicated agents for 6--48 h. Cells were either stained with propidium iodide for cell cycle analysis as described earlier \[[@CR54]\] or had RNA isolated for further analysis. The percentage of MCL-ICs was determined using procedures described in the "Isolation of MCL cells and MCL-ICs" section above.

Statistical analysis {#Sec17}
--------------------

Experimental data are reported as means or medians with standard deviation or error of mean, unless otherwise indicated. Differences between groups were calculated using the two-tailed Student's *t* test (GraphPad Prism, GraphPad Software, Inc, La Jolla, CA). *P* \< 0.05 was considered statistically significant.

Additional files {#Sec18}
================

Additional file 1: Figure S1.Wnt signaling pathway is active in MCL-ICs. Detection β-catenin expression and localization by immunofluorescence and confocal microscopy in (a) B-cells from healthy donors and in (b) freshly isolated MCL-ICs, and MCL-non-ICs.Additional file 2: Figure S2.Inhibition of Wnt signaling induce apoptosis of primary MCL cells. (a) Percentage apoptosis, sub-G1 analysis of primary MCL cells (*n* = 3) treated with vincristine (5 nM), doxorubicin (35 nM), or ibrutinib (10 μM), the Wnt inhibitors, CCT036477 (10 μM), iCRT14 (10 μM), or PKF118-310 (10 μM), for 48 h. \*Differences between treated and control group were significant *P* \< 0.05.Additional file 3: Figure S3.Hedgehog and Notch signaling pathways in MCL-ICs. Expression of mRNA encoding (a) Hedgehog signaling pathway transcription factors Gli1, Gli2, Gli3 and (b) Notch signaling target genes Hes1, Hes5 and Hey1 in freshly isolated MCL-ICs, and MCL-non-ICs relative to B-cells from healthy donors. Horizontal lines represent median for each group. Differences between MCL-ICs and MCL-non-ICs were significant (*P* \< 0.05) for Gli3, and Hey1. (c) Percentage of MCL-ICs evaluated by immunostaining and flow cytometry (as shown in Fig. [1a](#Fig1){ref-type="fig"}) of primary MCL cells (*n* = 3) treated with Hedgehog inhibitors LDE225 (5 μM), Cyclopamine (5 μM), GANT61 (5 μM) and Notch inhibitor RO4929097 (5 μM) for 48 h. \*Differences between treated and control group were significant *P* \< 0.05. Overexpression of Gli3, a repressor of hedgehog pathway \[[@CR55], [@CR56]\] in MCL-ICs and inability of hedgehog and notch signaling pathway inhibitors to decrease percentage of MCL-ICs, suggest that these pathways may not be effective targets for reducing the percentage of MCL-ICs.Additional file 4: Table S2.Clinical information of patients submitting primary MCL tissue for analysis.Additional file 5: Table S1.List of primers.

CSCs

:   Cancer stem cells

MCL

:   Mantle cell lymphoma

MCL-IC

:   Mantle cell lymphoma-initiating cells

R-CHOP

:   Rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone

R-hyperCVAD

:   Rituximab, cyclophosphamide, vincristine, adriamycin, dexamethasone

ALDH

:   Aldehyde dehydrogenase

SCID

:   Severe combined immunodeficiency

BTK

:   Burton tyrosine kinase

FZD

:   Frizzled

hMSC

:   human mesenchymal stem cells

GSK-3β

:   Glycogen synthase kinase

CAFC

:   Cobblestone area-forming cells
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